| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 77 | 2019 | 14289 | 2.750 |
Why?
|
| Brain Stem Neoplasms | 10 | 2022 | 108 | 2.390 |
Why?
|
| Neoplasms | 71 | 2021 | 15193 | 2.230 |
Why?
|
| Maximum Tolerated Dose | 49 | 2020 | 1290 | 2.180 |
Why?
|
| Child, Preschool | 132 | 2020 | 16273 | 2.120 |
Why?
|
| Camptothecin | 17 | 2010 | 517 | 2.080 |
Why?
|
| Central Nervous System Neoplasms | 16 | 2017 | 502 | 1.910 |
Why?
|
| Child | 149 | 2022 | 29154 | 1.740 |
Why?
|
| Salvage Therapy | 12 | 2019 | 2054 | 1.730 |
Why?
|
| Meningeal Neoplasms | 15 | 2011 | 441 | 1.710 |
Why?
|
| Topotecan | 15 | 2020 | 239 | 1.700 |
Why?
|
| Indoles | 8 | 2016 | 1009 | 1.650 |
Why?
|
| Glioma | 22 | 2020 | 1963 | 1.590 |
Why?
|
| Adolescent | 136 | 2020 | 31252 | 1.580 |
Why?
|
| Sarcoma, Ewing | 6 | 2019 | 406 | 1.550 |
Why?
|
| Cyclophosphamide | 15 | 2020 | 3001 | 1.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2020 | 15862 | 1.480 |
Why?
|
| Brain Neoplasms | 29 | 2020 | 4849 | 1.460 |
Why?
|
| Antimetabolites, Antineoplastic | 11 | 2013 | 1299 | 1.360 |
Why?
|
| Macaca mulatta | 24 | 2010 | 717 | 1.310 |
Why?
|
| Niacinamide | 3 | 2015 | 421 | 1.250 |
Why?
|
| Dose-Response Relationship, Drug | 46 | 2020 | 4938 | 1.240 |
Why?
|
| Neoplasm Recurrence, Local | 28 | 2021 | 10035 | 1.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 12 | 2015 | 588 | 1.210 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2020 | 5178 | 1.190 |
Why?
|
| Sirolimus | 3 | 2017 | 814 | 1.170 |
Why?
|
| Leukemia | 16 | 2019 | 1635 | 1.150 |
Why?
|
| Young Adult | 47 | 2020 | 21445 | 1.010 |
Why?
|
| Bone Neoplasms | 11 | 2019 | 2576 | 1.000 |
Why?
|
| Oncolytic Virotherapy | 4 | 2015 | 280 | 0.980 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 1946 | 0.960 |
Why?
|
| Drug Administration Schedule | 35 | 2020 | 3472 | 0.950 |
Why?
|
| Pyrroles | 5 | 2016 | 576 | 0.950 |
Why?
|
| Male | 149 | 2021 | 123000 | 0.940 |
Why?
|
| Area Under Curve | 26 | 2015 | 700 | 0.910 |
Why?
|
| Valproic Acid | 5 | 2020 | 263 | 0.900 |
Why?
|
| Guanine | 5 | 2012 | 151 | 0.890 |
Why?
|
| Infant | 65 | 2020 | 13310 | 0.860 |
Why?
|
| Injections, Spinal | 16 | 2012 | 257 | 0.860 |
Why?
|
| Medulloblastoma | 15 | 2013 | 540 | 0.850 |
Why?
|
| Antibodies, Monoclonal | 8 | 2014 | 4367 | 0.840 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2007 | 852 | 0.830 |
Why?
|
| Pediatrics | 7 | 2019 | 1141 | 0.830 |
Why?
|
| Topoisomerase I Inhibitors | 3 | 2011 | 75 | 0.820 |
Why?
|
| Medical Oncology | 6 | 2019 | 1423 | 0.810 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2021 | 4757 | 0.790 |
Why?
|
| Infusions, Intravenous | 30 | 2012 | 1382 | 0.790 |
Why?
|
| Rhabdomyosarcoma | 5 | 2015 | 341 | 0.790 |
Why?
|
| Pyrimidines | 11 | 2019 | 3518 | 0.770 |
Why?
|
| Glutamates | 3 | 2012 | 130 | 0.760 |
Why?
|
| Female | 130 | 2020 | 141928 | 0.760 |
Why?
|
| Neuroblastoma | 10 | 2021 | 686 | 0.760 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 580 | 0.740 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 242 | 0.710 |
Why?
|
| Humans | 184 | 2022 | 261506 | 0.710 |
Why?
|
| Dacarbazine | 7 | 2014 | 485 | 0.710 |
Why?
|
| Deoxycytidine | 5 | 2018 | 1353 | 0.700 |
Why?
|
| Sarcoma | 5 | 2014 | 1725 | 0.700 |
Why?
|
| Capecitabine | 2 | 2017 | 388 | 0.670 |
Why?
|
| Ketones | 1 | 2018 | 54 | 0.630 |
Why?
|
| Boronic Acids | 4 | 2012 | 362 | 0.630 |
Why?
|
| Furans | 1 | 2018 | 104 | 0.620 |
Why?
|
| Picornaviridae | 2 | 2014 | 24 | 0.620 |
Why?
|
| Pyrazines | 5 | 2012 | 495 | 0.620 |
Why?
|
| Tablets | 2 | 2017 | 53 | 0.610 |
Why?
|
| Emaciation | 1 | 2017 | 2 | 0.610 |
Why?
|
| Administration, Oral | 17 | 2020 | 1544 | 0.610 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2016 | 1248 | 0.590 |
Why?
|
| Enzyme Inhibitors | 10 | 2015 | 1879 | 0.560 |
Why?
|
| Benzimidazoles | 4 | 2020 | 428 | 0.560 |
Why?
|
| Adult | 74 | 2020 | 77950 | 0.550 |
Why?
|
| Pyrazoles | 6 | 2017 | 1471 | 0.550 |
Why?
|
| Reoviridae | 1 | 2015 | 38 | 0.520 |
Why?
|
| Protein Kinase C beta | 1 | 2014 | 35 | 0.510 |
Why?
|
| Depsipeptides | 2 | 2006 | 78 | 0.510 |
Why?
|
| Arabinonucleosides | 3 | 2006 | 437 | 0.510 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 1555 | 0.480 |
Why?
|
| Meninges | 2 | 2006 | 47 | 0.480 |
Why?
|
| Quinazolines | 8 | 2013 | 923 | 0.480 |
Why?
|
| Dioxoles | 2 | 2011 | 19 | 0.480 |
Why?
|
| Half-Life | 12 | 2010 | 259 | 0.480 |
Why?
|
| Recurrence | 15 | 2019 | 4758 | 0.470 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 669 | 0.460 |
Why?
|
| Treatment Outcome | 44 | 2019 | 32848 | 0.450 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 15 | 0.440 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2014 | 479 | 0.440 |
Why?
|
| Wilms Tumor | 2 | 2015 | 292 | 0.440 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 14889 | 0.430 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2011 | 24 | 0.430 |
Why?
|
| Pyridines | 6 | 2018 | 1244 | 0.420 |
Why?
|
| Organoplatinum Compounds | 3 | 2010 | 702 | 0.410 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 142 | 0.410 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2010 | 604 | 0.400 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 347 | 0.400 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2017 | 2796 | 0.400 |
Why?
|
| Ependymoma | 5 | 2021 | 242 | 0.400 |
Why?
|
| Thalidomide | 3 | 2010 | 569 | 0.390 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2014 | 709 | 0.380 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2020 | 387 | 0.360 |
Why?
|
| Cytarabine | 5 | 2006 | 1973 | 0.360 |
Why?
|
| Folic Acid Antagonists | 2 | 2007 | 45 | 0.360 |
Why?
|
| Supratentorial Neoplasms | 3 | 2021 | 78 | 0.350 |
Why?
|
| Central Nervous System Diseases | 3 | 2015 | 129 | 0.340 |
Why?
|
| Histones | 5 | 2013 | 1466 | 0.340 |
Why?
|
| Piperazines | 6 | 2010 | 2101 | 0.330 |
Why?
|
| Acyclovir | 1 | 2008 | 78 | 0.330 |
Why?
|
| Fluorouracil | 1 | 2013 | 1944 | 0.330 |
Why?
|
| Leukemic Infiltration | 2 | 2006 | 72 | 0.330 |
Why?
|
| Chromatography, High Pressure Liquid | 9 | 2006 | 548 | 0.330 |
Why?
|
| Cytidine | 3 | 1993 | 24 | 0.320 |
Why?
|
| Survival Rate | 14 | 2020 | 12221 | 0.320 |
Why?
|
| Valine | 1 | 2008 | 176 | 0.320 |
Why?
|
| Tissue Distribution | 4 | 2019 | 875 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.310 |
Why?
|
| Meningitis | 3 | 2006 | 112 | 0.310 |
Why?
|
| Metabolic Clearance Rate | 14 | 2009 | 231 | 0.310 |
Why?
|
| Hematologic Neoplasms | 3 | 2015 | 1870 | 0.300 |
Why?
|
| Hydroxamic Acids | 4 | 2022 | 442 | 0.300 |
Why?
|
| Patient Participation | 2 | 2010 | 446 | 0.300 |
Why?
|
| Phenylacetates | 2 | 2004 | 20 | 0.290 |
Why?
|
| Combined Modality Therapy | 17 | 2019 | 8865 | 0.290 |
Why?
|
| Astrocytoma | 3 | 2022 | 321 | 0.290 |
Why?
|
| Sulfonamides | 2 | 2013 | 1823 | 0.280 |
Why?
|
| Prognosis | 14 | 2020 | 21713 | 0.280 |
Why?
|
| Sesquiterpenes | 1 | 2006 | 68 | 0.280 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2008 | 328 | 0.280 |
Why?
|
| Neutropenia | 11 | 2013 | 968 | 0.270 |
Why?
|
| Rhabdoid Tumor | 4 | 2011 | 110 | 0.270 |
Why?
|
| Carbazoles | 3 | 2008 | 87 | 0.270 |
Why?
|
| Phototherapy | 3 | 2012 | 75 | 0.270 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2011 | 882 | 0.270 |
Why?
|
| Animals | 40 | 2021 | 59536 | 0.270 |
Why?
|
| Azepines | 2 | 2019 | 124 | 0.260 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2008 | 726 | 0.260 |
Why?
|
| Catheters, Indwelling | 3 | 2004 | 374 | 0.250 |
Why?
|
| Teratoma | 4 | 2011 | 236 | 0.250 |
Why?
|
| Prodrugs | 2 | 2006 | 217 | 0.250 |
Why?
|
| Cerebellar Neoplasms | 3 | 2007 | 434 | 0.240 |
Why?
|
| Injections, Intravenous | 7 | 2013 | 573 | 0.240 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 698 | 0.240 |
Why?
|
| Farnesyltranstransferase | 3 | 2010 | 122 | 0.240 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 260 | 0.230 |
Why?
|
| Neoplasm Staging | 13 | 2017 | 13658 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2014 | 3251 | 0.230 |
Why?
|
| Methotrexate | 5 | 2006 | 999 | 0.230 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 231 | 0.230 |
Why?
|
| Bortezomib | 4 | 2012 | 543 | 0.230 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 139 | 0.230 |
Why?
|
| Quinolones | 3 | 2010 | 160 | 0.220 |
Why?
|
| Models, Theoretical | 2 | 2004 | 785 | 0.220 |
Why?
|
| Kidney Neoplasms | 3 | 2015 | 3022 | 0.220 |
Why?
|
| Cerebrospinal Fluid | 4 | 2004 | 120 | 0.210 |
Why?
|
| Retreatment | 3 | 2019 | 452 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2015 | 1533 | 0.210 |
Why?
|
| Thienamycins | 1 | 2001 | 23 | 0.210 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 64 | 0.210 |
Why?
|
| Phenytoin | 1 | 2002 | 71 | 0.200 |
Why?
|
| Osteosarcoma | 6 | 2016 | 929 | 0.200 |
Why?
|
| Paclitaxel | 4 | 2009 | 1996 | 0.200 |
Why?
|
| Glutamine | 1 | 2003 | 299 | 0.200 |
Why?
|
| Nanoshells | 2 | 2012 | 43 | 0.200 |
Why?
|
| Antiviral Agents | 3 | 1999 | 1230 | 0.200 |
Why?
|
| Pemetrexed | 3 | 2012 | 102 | 0.190 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2014 | 17 | 0.190 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 200 | 0.190 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 184 | 0.190 |
Why?
|
| Jugular Veins | 1 | 2000 | 107 | 0.190 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 69 | 0.180 |
Why?
|
| Anticonvulsants | 2 | 2009 | 431 | 0.180 |
Why?
|
| Oncolytic Viruses | 2 | 2013 | 204 | 0.180 |
Why?
|
| Glucuronosyltransferase | 3 | 2009 | 104 | 0.170 |
Why?
|
| Mass Spectrometry | 4 | 2006 | 702 | 0.170 |
Why?
|
| Health Planning Councils | 1 | 2019 | 2 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 2 | 2014 | 144 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2016 | 665 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2012 | 355 | 0.160 |
Why?
|
| Ganciclovir | 1 | 1999 | 174 | 0.160 |
Why?
|
| Blood-Brain Barrier | 3 | 2010 | 238 | 0.160 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.160 |
Why?
|
| Benzamides | 7 | 2010 | 1832 | 0.160 |
Why?
|
| Prosthesis Implantation | 1 | 2000 | 263 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 10331 | 0.160 |
Why?
|
| Erwinia | 1 | 2017 | 7 | 0.160 |
Why?
|
| Dexamethasone | 3 | 2012 | 1450 | 0.160 |
Why?
|
| Bevacizumab | 2 | 2020 | 938 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Time Factors | 15 | 2018 | 12926 | 0.150 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2017 | 22 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive | 3 | 2006 | 100 | 0.150 |
Why?
|
| Diencephalon | 1 | 2017 | 14 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 2979 | 0.150 |
Why?
|
| ErbB Receptors | 6 | 2013 | 2295 | 0.150 |
Why?
|
| Neoplasm Proteins | 6 | 2015 | 3230 | 0.150 |
Why?
|
| Asparaginase | 1 | 2017 | 184 | 0.150 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.150 |
Why?
|
| Taxoids | 2 | 1999 | 967 | 0.150 |
Why?
|
| Microtubules | 1 | 2018 | 270 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 86 | 0.140 |
Why?
|
| Ifosfamide | 3 | 2009 | 344 | 0.140 |
Why?
|
| Foot | 1 | 2017 | 104 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 272 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 2017 | 128 | 0.140 |
Why?
|
| Zalcitabine | 1 | 1995 | 3 | 0.140 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 615 | 0.140 |
Why?
|
| Hand | 1 | 2017 | 170 | 0.140 |
Why?
|
| Anilides | 1 | 2018 | 268 | 0.140 |
Why?
|
| Models, Biological | 5 | 2010 | 3254 | 0.140 |
Why?
|
| Benzoquinones | 3 | 2007 | 108 | 0.140 |
Why?
|
| Carboplatin | 3 | 2011 | 823 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 661 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 1756 | 0.130 |
Why?
|
| Benzene Derivatives | 1 | 2015 | 23 | 0.130 |
Why?
|
| Propionates | 1 | 2015 | 71 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2012 | 2292 | 0.130 |
Why?
|
| Aminoglycosides | 2 | 2008 | 220 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2018 | 279 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2014 | 324 | 0.130 |
Why?
|
| DNA Modification Methylases | 2 | 2013 | 172 | 0.130 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1742 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 10001 | 0.130 |
Why?
|
| Growth Plate | 1 | 2014 | 46 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2017 | 574 | 0.120 |
Why?
|
| Sulfones | 1 | 2015 | 143 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2001 | 945 | 0.120 |
Why?
|
| Thrombocytopenia | 5 | 2013 | 846 | 0.120 |
Why?
|
| Doxorubicin | 4 | 2020 | 3005 | 0.120 |
Why?
|
| Etoposide | 3 | 2006 | 870 | 0.120 |
Why?
|
| DNA Repair Enzymes | 2 | 2013 | 237 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Posture | 1 | 1995 | 215 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2015 | 1391 | 0.120 |
Why?
|
| Syndrome | 1 | 2017 | 1351 | 0.120 |
Why?
|
| Survival Analysis | 9 | 2013 | 9180 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 960 | 0.120 |
Why?
|
| Urate Oxidase | 2 | 2005 | 32 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 3821 | 0.110 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 29 | 0.110 |
Why?
|
| Tretinoin | 2 | 2010 | 623 | 0.110 |
Why?
|
| Biological Availability | 2 | 2020 | 214 | 0.110 |
Why?
|
| Oligonucleotides | 1 | 2013 | 227 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2022 | 612 | 0.110 |
Why?
|
| Uracil | 1 | 1992 | 64 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2008 | 598 | 0.110 |
Why?
|
| Mice, SCID | 7 | 2013 | 1869 | 0.110 |
Why?
|
| Powders | 1 | 2011 | 23 | 0.110 |
Why?
|
| Nitriles | 2 | 2015 | 906 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2010 | 1443 | 0.100 |
Why?
|
| Busulfan | 2 | 2006 | 764 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1559 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2017 | 2803 | 0.100 |
Why?
|
| Cisplatin | 3 | 2004 | 2432 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 1029 | 0.100 |
Why?
|
| Pyridones | 1 | 2014 | 348 | 0.100 |
Why?
|
| Indazoles | 1 | 2013 | 297 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 806 | 0.100 |
Why?
|
| Acylation | 1 | 2010 | 25 | 0.100 |
Why?
|
| Imatinib Mesylate | 5 | 2008 | 1665 | 0.100 |
Why?
|
| Lipocalins | 1 | 2011 | 54 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2010 | 368 | 0.100 |
Why?
|
| Thiourea | 1 | 2010 | 18 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 81 | 0.090 |
Why?
|
| Altruism | 1 | 2010 | 34 | 0.090 |
Why?
|
| Vinblastine | 1 | 2011 | 453 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 630 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 4821 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2021 | 5270 | 0.090 |
Why?
|
| Telomerase | 1 | 2013 | 525 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 541 | 0.090 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 5159 | 0.090 |
Why?
|
| Epothilones | 1 | 2010 | 54 | 0.090 |
Why?
|
| Acridines | 2 | 2000 | 12 | 0.090 |
Why?
|
| Hyperthermia, Induced | 2 | 2012 | 510 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1429 | 0.090 |
Why?
|
| Amifostine | 2 | 2003 | 97 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2014 | 9244 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 1547 | 0.090 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 7222 | 0.090 |
Why?
|
| Radiotherapy Dosage | 3 | 2013 | 3842 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2008 | 363 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 342 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2014 | 4804 | 0.080 |
Why?
|
| Metalloporphyrins | 1 | 2008 | 30 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 419 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 262 | 0.080 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 57 | 0.080 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2008 | 53 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1538 | 0.080 |
Why?
|
| Pons | 1 | 2008 | 51 | 0.080 |
Why?
|
| Protein Binding | 2 | 2006 | 3438 | 0.080 |
Why?
|
| Glucuronates | 1 | 2008 | 11 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2011 | 842 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.080 |
Why?
|
| Immunohistochemistry | 7 | 2007 | 7548 | 0.080 |
Why?
|
| Acetylation | 2 | 2006 | 508 | 0.080 |
Why?
|
| Drug Interactions | 3 | 2009 | 553 | 0.080 |
Why?
|
| Lymphocytes | 1 | 1993 | 1234 | 0.080 |
Why?
|
| Carmustine | 1 | 2008 | 214 | 0.080 |
Why?
|
| Headache | 2 | 2007 | 163 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 1489 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2005 | 198 | 0.080 |
Why?
|
| Lymphoma | 2 | 2007 | 1467 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2007 | 65 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 1823 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.070 |
Why?
|
| Mice | 13 | 2021 | 34495 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 1062 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 90 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 143 | 0.070 |
Why?
|
| Oxides | 1 | 2007 | 211 | 0.070 |
Why?
|
| Arsenicals | 1 | 2007 | 201 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 902 | 0.070 |
Why?
|
| Thiazoles | 1 | 2011 | 726 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2008 | 429 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2008 | 83 | 0.070 |
Why?
|
| Hydrazines | 1 | 2008 | 208 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2007 | 248 | 0.070 |
Why?
|
| Melphalan | 2 | 2002 | 834 | 0.070 |
Why?
|
| Cell Line, Tumor | 10 | 2012 | 14551 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 250 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3101 | 0.070 |
Why?
|
| Aziridines | 2 | 1998 | 17 | 0.070 |
Why?
|
| Risk Assessment | 6 | 2011 | 6869 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 886 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2011 | 1335 | 0.070 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 12 | 0.060 |
Why?
|
| Vincristine | 3 | 2020 | 1511 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 87 | 0.060 |
Why?
|
| Imidazoles | 1 | 2010 | 999 | 0.060 |
Why?
|
| Biomarkers | 3 | 2012 | 5047 | 0.060 |
Why?
|
| Hyperuricemia | 1 | 2005 | 34 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2007 | 215 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2007 | 5395 | 0.060 |
Why?
|
| Heart | 1 | 2011 | 1223 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2005 | 116 | 0.060 |
Why?
|
| Spinal Puncture | 1 | 2004 | 63 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 210 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2008 | 747 | 0.060 |
Why?
|
| Cell Division | 2 | 2005 | 2489 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 528 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2007 | 430 | 0.060 |
Why?
|
| Thiophenes | 1 | 2005 | 148 | 0.060 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 669 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 589 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 7702 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 534 | 0.060 |
Why?
|
| Pancreatitis | 3 | 2008 | 267 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 71 | 0.060 |
Why?
|
| Biotransformation | 1 | 2003 | 93 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 864 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 351 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2004 | 81 | 0.060 |
Why?
|
| Phenylbutyrates | 1 | 2004 | 59 | 0.060 |
Why?
|
| Disease Progression | 4 | 2014 | 6682 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2005 | 382 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2017 | 12873 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 566 | 0.060 |
Why?
|
| Triazines | 1 | 2004 | 117 | 0.060 |
Why?
|
| Cell Survival | 4 | 2006 | 3045 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2008 | 2358 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 288 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2005 | 1371 | 0.060 |
Why?
|
| Morphine | 1 | 2005 | 308 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 1385 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.060 |
Why?
|
| Cyclins | 1 | 2004 | 456 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2006 | 842 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2007 | 554 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2013 | 3536 | 0.050 |
Why?
|
| Liposomes | 1 | 2004 | 684 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2006 | 649 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2004 | 576 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1144 | 0.050 |
Why?
|
| Phenobarbital | 1 | 2002 | 48 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 37905 | 0.050 |
Why?
|
| Ondansetron | 1 | 2002 | 42 | 0.050 |
Why?
|
| Peptides | 1 | 2008 | 1479 | 0.050 |
Why?
|
| Pineal Gland | 1 | 2002 | 50 | 0.050 |
Why?
|
| Piperidines | 1 | 2007 | 1035 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 249 | 0.050 |
Why?
|
| Vomiting | 2 | 2007 | 354 | 0.050 |
Why?
|
| Pinealoma | 1 | 2002 | 49 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 575 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 3719 | 0.050 |
Why?
|
| Nausea | 2 | 2007 | 525 | 0.050 |
Why?
|
| Drug Resistance | 2 | 1993 | 587 | 0.050 |
Why?
|
| Rituximab | 1 | 2006 | 1528 | 0.050 |
Why?
|
| Pharmaceutic Aids | 1 | 2000 | 3 | 0.050 |
Why?
|
| Infant, Newborn | 6 | 2008 | 8223 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 4298 | 0.050 |
Why?
|
| Povidone | 1 | 2000 | 13 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 629 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 810 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2008 | 1529 | 0.050 |
Why?
|
| Uric Acid | 1 | 2001 | 75 | 0.050 |
Why?
|
| Cefazolin | 1 | 2000 | 25 | 0.050 |
Why?
|
| Genotype | 1 | 2009 | 4109 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2007 | 3341 | 0.050 |
Why?
|
| Isoflurane | 1 | 2000 | 67 | 0.050 |
Why?
|
| Genetic Therapy | 2 | 2000 | 1616 | 0.050 |
Why?
|
| Neoplasm Transplantation | 3 | 2010 | 1519 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 3639 | 0.050 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 62 | 0.050 |
Why?
|
| Phenylenediamines | 1 | 2000 | 23 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2004 | 793 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2000 | 208 | 0.050 |
Why?
|
| Subarachnoid Space | 1 | 2000 | 36 | 0.050 |
Why?
|
| Penicillins | 1 | 2000 | 143 | 0.050 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1999 | 34 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2007 | 1549 | 0.040 |
Why?
|
| Thioguanine | 1 | 1999 | 68 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 2008 | 1910 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 148 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 315 | 0.040 |
Why?
|
| Buprenorphine | 1 | 2000 | 96 | 0.040 |
Why?
|
| Carbamates | 1 | 1999 | 77 | 0.040 |
Why?
|
| Patient Selection | 5 | 2011 | 2055 | 0.040 |
Why?
|
| Hospitals, Pediatric | 3 | 2011 | 773 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1582 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 3981 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 749 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2009 | 515 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 11538 | 0.040 |
Why?
|
| Drug Eruptions | 3 | 2008 | 256 | 0.040 |
Why?
|
| Cytotoxins | 1 | 1998 | 66 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 335 | 0.040 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1998 | 36 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5687 | 0.040 |
Why?
|
| Sarcoma, Clear Cell | 1 | 1998 | 41 | 0.040 |
Why?
|
| Apoptosis | 3 | 2010 | 7591 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 429 | 0.040 |
Why?
|
| SMARCB1 Protein | 2 | 2011 | 109 | 0.040 |
Why?
|
| Bone Marrow Diseases | 2 | 2008 | 177 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 313 | 0.040 |
Why?
|
| Pain | 1 | 2005 | 1658 | 0.030 |
Why?
|
| Lamivudine | 1 | 1995 | 28 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 4988 | 0.030 |
Why?
|
| Seizures | 1 | 2002 | 989 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 164 | 0.030 |
Why?
|
| Diarrhea | 2 | 2010 | 686 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 176 | 0.030 |
Why?
|
| Glucosides | 2 | 2008 | 64 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2015 | 49 | 0.030 |
Why?
|
| Brain Stem | 1 | 1996 | 175 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2009 | 1313 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 2927 | 0.030 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2008 | 297 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2011 | 362 | 0.030 |
Why?
|
| Radiotherapy | 3 | 2008 | 1824 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2330 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 1082 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 550 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 289 | 0.030 |
Why?
|
| Cell Cycle | 3 | 2005 | 2084 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 1039 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1992 | 425 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 895 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 333 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 218 | 0.030 |
Why?
|
| Middle Aged | 5 | 2007 | 86204 | 0.030 |
Why?
|
| Uridine Kinase | 1 | 1993 | 4 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 889 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1993 | 52 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2010 | 6150 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 1993 | 83 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1993 | 227 | 0.030 |
Why?
|
| Didanosine | 1 | 1992 | 5 | 0.030 |
Why?
|
| Fatigue | 2 | 2010 | 1239 | 0.030 |
Why?
|
| Platelet Count | 2 | 2003 | 490 | 0.030 |
Why?
|
| Retroviridae Infections | 1 | 1991 | 17 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 2002 | 114 | 0.020 |
Why?
|
| Carbohydrate Sequence | 1 | 2011 | 38 | 0.020 |
Why?
|
| Thiotepa | 1 | 1991 | 118 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 622 | 0.020 |
Why?
|
| Philadelphia | 1 | 2011 | 38 | 0.020 |
Why?
|
| Asparagine | 1 | 2011 | 38 | 0.020 |
Why?
|
| Trypsin | 1 | 2011 | 140 | 0.020 |
Why?
|
| Mercaptopurine | 1 | 1991 | 130 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2010 | 33 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 212 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 2992 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2010 | 82 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 208 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 145 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 2010 | 78 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 148 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2010 | 55 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1995 | 691 | 0.020 |
Why?
|
| United States | 3 | 2018 | 15433 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 6207 | 0.020 |
Why?
|
| Species Specificity | 1 | 1990 | 777 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 2 | 2010 | 2518 | 0.020 |
Why?
|
| Hallucinations | 1 | 2009 | 35 | 0.020 |
Why?
|
| Dogs | 1 | 1990 | 1155 | 0.020 |
Why?
|
| Steroids | 1 | 2010 | 356 | 0.020 |
Why?
|
| Lomustine | 1 | 2008 | 39 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 110 | 0.020 |
Why?
|
| Arthralgia | 1 | 2009 | 89 | 0.020 |
Why?
|
| DNA Repair | 2 | 2008 | 1872 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2008 | 58 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 211 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2011 | 2527 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2007 | 54 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2007 | 104 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 268 | 0.020 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2007 | 32 | 0.020 |
Why?
|
| Dermatitis | 1 | 2007 | 60 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 41 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 63 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 175 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 862 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 1664 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 388 | 0.020 |
Why?
|
| Proteome | 1 | 2011 | 561 | 0.020 |
Why?
|
| Sarcoma, Synovial | 1 | 2008 | 119 | 0.020 |
Why?
|
| Lasers | 1 | 2007 | 198 | 0.020 |
Why?
|
| Bilirubin | 1 | 2008 | 221 | 0.020 |
Why?
|
| Incidence | 1 | 1997 | 5673 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2006 | 70 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 256 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1997 | 4320 | 0.020 |
Why?
|
| Constipation | 1 | 2007 | 177 | 0.020 |
Why?
|
| Procarbazine | 1 | 2006 | 69 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 161 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2002 | 503 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 543 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 193 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 26 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 202 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 334 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 1048 | 0.020 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2006 | 87 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 178 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2006 | 206 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 400 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1996 | 1797 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 408 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2004 | 23 | 0.020 |
Why?
|
| Cyclin D2 | 1 | 2004 | 40 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2007 | 369 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2007 | 333 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1993 | 3890 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 42 | 0.020 |
Why?
|
| DNA Damage | 1 | 1993 | 1954 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2005 | 278 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 4233 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 931 | 0.020 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2004 | 35 | 0.020 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2006 | 4078 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 311 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 1506 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2010 | 1987 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2004 | 129 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 6550 | 0.010 |
Why?
|
| Brain | 2 | 2012 | 4113 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4053 | 0.010 |
Why?
|
| Proteomics | 1 | 2011 | 1380 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 6089 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 448 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2315 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 335 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 285 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 311 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 324 | 0.010 |
Why?
|
| Aniline Compounds | 1 | 2004 | 177 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Monosomy | 1 | 2002 | 95 | 0.010 |
Why?
|
| DNA Adducts | 1 | 2003 | 210 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2002 | 169 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 6086 | 0.010 |
Why?
|
| Pneumonia | 1 | 2007 | 751 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 477 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 1360 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 465 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6100 | 0.010 |
Why?
|
| Phosphorus | 1 | 2001 | 65 | 0.010 |
Why?
|
| Uricosuric Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Probenecid | 1 | 2000 | 5 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 2669 | 0.010 |
Why?
|
| Aldehyde Oxidase | 1 | 1999 | 8 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1656 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 4532 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2000 | 191 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 8873 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 98 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 3203 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 1439 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1493 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 2134 | 0.010 |
Why?
|
| Filgrastim | 1 | 1999 | 191 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 2961 | 0.010 |
Why?
|
| General Surgery | 1 | 2002 | 326 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 4917 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 2022 | 0.010 |
Why?
|
| Anemia | 1 | 2003 | 689 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2002 | 1005 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 3033 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 1618 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 4549 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1995 | 184 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 2488 | 0.010 |
Why?
|
| Haplorhini | 1 | 1994 | 130 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3343 | 0.010 |
Why?
|
| Tibia | 1 | 1994 | 131 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 7226 | 0.010 |
Why?
|
| Anxiety | 1 | 2000 | 1179 | 0.010 |
Why?
|
| Mutation | 1 | 2013 | 15179 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 2287 | 0.010 |
Why?
|
| Absorption | 1 | 1992 | 81 | 0.010 |
Why?
|
| Drug Industry | 1 | 1991 | 88 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 17523 | 0.010 |
Why?
|
| Acute Disease | 1 | 1994 | 2422 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 362 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 7551 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 4892 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 29902 | 0.000 |
Why?
|
| Aged | 1 | 2005 | 70117 | 0.000 |
Why?
|